Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsWest Pharmaceutical discloses material cyberattack with data theft and global disruptions
Filed May 11, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
On May 7, 2026, West disclosed a material cyberattack where unauthorized parties stole data and encrypted systems. The attack was detected May 4, prompting the company to take systems offline globally and engage forensic experts.
Item 8.01 view on EDGAR → -
high
The cyberattack caused temporary global operational disruptions. Core systems and critical processes (shipping, receiving, manufacturing) have restarted at some sites, but full restoration across all locations has no finalized timeline.
Item 8.01 view on EDGAR → -
high
West has not yet determined whether the incident will materially impact financial condition or operating results, creating uncertainty around potential costs, lost revenue, or other financial consequences.
Item 8.01 view on EDGAR → -
medium
The investigation into the full scope of compromised data is ongoing. Law enforcement has been notified and forensic experts are engaged to assess the breach.
Item 8.01 view on EDGAR →
Summary
West Pharmaceutical Services disclosed a material cybersecurity breach on May 7, 2026, after detecting unauthorized access three days earlier. Attackers exfiltrated company data and encrypted systems, forcing West to take systems offline globally as a containment measure.
While core enterprise systems have been restored and critical manufacturing, shipping, and receiving operations have resumed at some facilities, the company has not provided a timeline for complete restoration across all sites. Retail investors should care because the financial impact remains unknown. West explicitly stated it cannot yet determine whether the attack will materially affect financial results.
Potential costs include breach remediation, legal expenses, regulatory fines, customer compensation, and lost revenue from operational downtime. The company's role as a supplier to pharmaceutical and medical device manufacturers means disruptions could affect customer relationships and future contracts. Watch for West's next quarterly earnings call and any subsequent 8-K filings for updates on: (1) total financial impact and insurance recovery, (2) timeline for full operational restoration, (3) scope of data compromised and potential regulatory or legal exposure, and (4) any customer losses or contract impacts from the disruption.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
West Pharmaceutical furnished a website statement under Regulation FD disclosure with no material details provided in the 8-K body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
A copy of the Company’s statement on its website regarding this matter is furnished as Exhibit 99.1 to this report and is incorporated into this Item 7.01 by reference thereto.
The company disclosed information under Regulation FD by furnishing a website statement as Exhibit 99.1. The 8-K body does not specify the subject matter of the statement, making it impossible to assess materiality without reviewing the exhibit itself. This is a procedural disclosure with no substantive details in the filing text.
Event · Item 9.01 — Financial Statements and Exhibits
West Pharmaceutical Services filed an 8-K attaching a company website statement dated May 11, 2026; no material business event disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1West Pharmaceutical Services, Inc. Company Website Statement, dated May 11, 2026 (furnished, not filed).
The company furnished a website statement dated May 11, 2026 as Exhibit 99.1. The 8-K body does not describe the content of this statement, and it is marked as furnished rather than filed, meaning it is not incorporated by reference into any SEC registration statements.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify